Habibzadeh Mohammad Reza, Thai Hoang, Movahed Mohammad Reza
The Southern Arizona VA Health Care System, Tucson, AZ, USA.
J Invasive Cardiol. 2011 May;23(5):202-6.
No-reflow is a failure to restore normal coronary flow despite appropriate treatment of coronary obstruction. It is most commonly seen during interventions in saphenous vein grafts and is associated with poor outcome. The cause of no-reflow is complex and multifactorial. Various mechanisms including vasospasm and distal embolization of debris released during the intervention have been explained as the cause of no-reflow. Treatment to prevent or reverse no-reflow includes, but is not limited to, protective devices and intracoronary vasodilators. Intracoronary nicardipine seems to be the best option in preventing no-reflow regarding its minimal systemic side effects, modest negative inotropic and chronotropic effects, duration of action and feasibility of use. The goal of this manuscript is to review the effects of prophylactic intragraft nicardipine injection for prevention of no-reflow during saphenous vein graft intervention.
无复流是指尽管对冠状动脉阻塞进行了适当治疗，但冠状动脉血流仍未能恢复正常。它最常见于隐静脉移植血管介入治疗期间，且与不良预后相关。无复流的病因复杂且具有多因素性。包括血管痉挛和介入过程中释放的碎片远端栓塞等多种机制已被解释为无复流的原因。预防或逆转无复流的治疗方法包括但不限于保护装置和冠状动脉内血管扩张剂。冠状动脉内尼卡地平因其最小的全身副作用、适度的负性肌力和变时作用、作用持续时间以及使用的可行性，似乎是预防无复流的最佳选择。本手稿的目的是综述预防性移植血管内注射尼卡地平对预防隐静脉移植血管介入治疗期间无复流的效果。
